The amendment to the Drugs Rules, 1945 replacing Form 11 licensing with an acknowledgement-based system is a necessary but insufficient step to make India a global pharmaceutical R&D hub. Critically examine.

Form 11 of the Drugs Rules, 1945 required a prior licence from the CDSCO even to import a milligram of a reference standard for laboratory testing. The Health Ministry's June 2026 draft amendment replacing this with an acknowledgement-based prior-intimation system [1] removes a real bottleneck, but R&D leadership rests on capabilities a procedural rule cannot supply.

Why the step is necessary

• Removes a disproportionate compliance load: import of drugs in small quantities for analytical and non-clinical testing may now proceed on the acknowledgement auto-generated on filing intimation, ending licensing delays for start-ups and testing laboratories [1].
• Accelerates the pipeline's first mile: in-vitro, stability and analytical characterisation precede clinical trials; delay here pushes the entire development cycle back.
• Risk-tiered, not deregulatory: sex hormones, cytotoxic drugs, beta-lactam drugs and biologics containing live microorganisms remain under prior licence [1]; narcotics stay controlled under NDPS/UN convention obligations — safety is preserved.
• Coheres with a wider reform wave: the Jan Vishwas (Amendment of Provisions) Bill, 2026 decriminalised 717 provisions across Central Acts, including the Drugs and Cosmetics Act, 1940, substituting graded monetary penalties for imprisonment in minor violations [2].

Why it remains insufficient

• Narrow scope: clinical-trial, commercial and therapeutic imports still follow the full approval pathway; the binding constraints on new-drug research are untouched.
• Institutional capacity: outcomes depend on CDSCO's assessors and laboratory infrastructure — a portal cannot substitute for regulatory strength.
• Self-certification needs post-market teeth: moving from pre-approval to intimation demands audit and surveillance to deter diversion of "small quantity" imports.
• Regulatory unpredictability: recurring churn in the same Rules — such as the 2025 withdrawal of the cough-syrup village-sale exemption [3] — complicates long-horizon research investment.
• Ecosystem deficits: modest private R&D spending, weak academia–industry translation and API import dependence lie outside the rulebook.

The amendment is therefore an enabling correction rather than a transformative one: it lowers the entry barrier to research without creating research capacity. Pairing it with a well-staffed CDSCO, predictable consultative rule-making and sustained investment in translational research would convert procedural ease into innovation. Read with the Jan Vishwas reforms, it points the right way — a regulator that facilitates innovation while holding firm on patient safety.